摘要
目的探讨阿托伐他汀钙片联合辛伐他汀片治疗冠心病的疗效及安全性。方法选取吉林市人民医院2018年1月至2019年1月收治的128例冠心病患者,按随机数字表法分为观察组和对照组,每组64例。对照组给予辛伐他汀片治疗,观察组在对照组基础上联合阿托伐他汀钙片治疗。比较两组治疗前后的血脂联素(APN)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平、动脉粥样硬化程度、肱动脉内径变化百分率(D)和不良反应发生情况。结果治疗前,两组APN水平比较,差异无统计学意义(P>0.05)。治疗后,观察组APN水平明显高于本组治疗前和同期对照组,差异有统计学意义(P<0.05)。治疗前,两组TC、TG、LDL-C和HDL-C水平比较,差异无统计学意义(P>0.05)。治疗后,观察组TC、TG和LDL-C均低于本组治疗前和同期对照组,HDL-C水平高于本组治疗前和同期对照组,差异有统计学意义(P<0.05)。治疗前,两组IMT、Crouse积分、Gensini评分和D值比较,差异均无统计学意义(P>0.05)。治疗后,观察组Crouse积分、Gensini评分低于本组治疗前和同期对照组,D值高于本组治疗前和同期对照组,差异有统计学意义(P<0.05)。两组均未出现明显不良反应。结论阿托伐他汀钙片联合辛伐他汀片治疗冠心病能提高APN水平,改善脂代谢异常、动脉硬化程度和血管内皮舒张功能,疗效显著,安全性较高。
Objective To investigate the efficacy and safety of atorvastatin calcium tablets combined with simvastatin tablets in the treatment of coronary heart disease.Methods A total of 128 patients with coronary heart disease admitted to Jilin People's Hospital from January 2018 to January 2019 were randomly divided into observation group and control group,with 64 cases in each group.The control group was treated with simvastatin tablets,and the observation group was treated with atorvastatin calcium tablets on the basis of the control group.Comparison of serum adiponectin(APN),total cholesterol(TC),triglyceride(TG),lowdensity lipoprotein cholesterol(LDL-C)and high-density lipoprotein cholesterol(HDL-C)levels,arteries before and after treatment The degree of atherosclerosis,the percentage change of the radial diameter of the radial artery(D)and the occurrence of adverse reactions.Results Before treatment,there was no significant difference in APN levels between the two groups(P>0.05).After treatment,the APN level in the observation group was significantly higher than that in the control group and the control group before the treatment,the difference was statistically significant(P<0.05).Before treatment,the levels of TC,TG,LDL-C and HDL-C in the two groups were not significantly different(P>0.05).After treatment,the TC,TG and LDL-C in the observation group were lower than those in the control group and the control group before operation,and the HDL-C level was higher than that in the control group and the control group before the treatment,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in IMT,Crouse score,Gensini score and D value between the two groups(P>0.05).After treatment,the Crouse score and Gensini score in the observation group were lower than those in the control group and the control group before the treatment.The D value was higher than that in the control group and the control group(P<0.05).There were no significant adverse reactions in either group
作者
顾纪新
GU Jixin(Jilin People’s Hospital,Jilin 132000,China)
出处
《大医生》
2019年第11期148-150,共3页
Doctor
关键词
阿托伐他汀
心血管药物
冠心病
动脉粥样硬化
atorvastatin
cardiovascular drugs
coronary heart disease
atherosclerosis
